Come Meet with DELFI Diagnostics at the 2025 AACR Annual Meeting
Visit Booth #2060 to discover how our fragmentomic analysis is revolutionizing precision oncology and treatment response assessment.
© 2025 DELFI Diagnostics, Inc. All rights reserved. FirstLook is a trademark of DELFI Diagnostics, Inc. used worldwide.
General Inquiry: clientservices@delfidiagnostics.com
1810 Embarcadero Road, Suite 100
Palo Alto, CA 94303
2809 Boston Street, Suite 503
Baltimore, MD 21224
800-589-2182
Follow us:
About DELFI Diagnostics
DELFI Diagnostics is a pioneering leader in cancer detection and monitoring through fragmentomics. Our technology analyzes unique DNA fragmentation patterns in the bloodstream to detect cancer earlier and monitor treatment effectiveness with high sensitivity. DELFI's non-invasive liquid biopsy approach aims to improve patient outcomes and accelerate pharmaceutical development through data-driven insights powered by machine learning and genome-wide analysis.
DELFI-TF (DELFI-Tumor Fraction)
DELFI-TF is a tumor-naive and mutation-independent cancer treatment monitoring assay that can detect disease progression ahead of imaging assessment (RECIST). DELFI Diagnostics is collaborating with several pharmaceutical companies to apply the DELFI-TF as a pharmacodynamic monitoring tool for the portfolio management of Phase I-II clinical trials.
FirstLook Lung
Commercialized in 2023, the FirstLook Lung blood test is designed to be a convenient first step that can be offered to patients during a routine medical visit to help identify lung cancer early, when it’s most treatable.
Learn More About DELFI’s AI-Powered, Fragmentomics Platform at AACR
Podium Presentations
Title: Genomic and fragmentomic landscapes of cell-free DNA for early cancer detection
Presenter: Victor E. Velculescu, MD, PhD
Date & Time: Tuesday, April 28, 11:06 AM - 11:26 AM CT
Location: Room S100 BC (Grand Ballroom BC) - McCormick Place South (Level 1)
Session: AED02 - Opportunities in Cancer Early Detection using Next Generation Liquid Biopsies
Title: Analysis of lung cancer clinical characteristics using cell-free DNA fragmentomes
Presenting Author: Lorenzo Rinaldi, PhD
Date & Time: Tuesday, April 28, 9:00 AM - 12:00 PM CT
Poster Number: Section 28, Poster 29
Session: PO.CL01.02 - Liquid Biopsy: Circulating Nucleic Acids 5 / Circulating Tumor Cells 2
Poster Presentations
Sunday, April 27: 12:00 PM - 5:00 PM
Monday, April 28: 9:00 AM - 5:00 PM
Tuesday, April 29: 9:00 AM - 5:00 PM
Wednesday, April 30: 9:00 AM - 12:00 PM
Visit Our Booth & Meet DELFI’s Researchers
Booth Information
Title: Leveraging the cfDNA fragmentome to predict immunotherapy response
Presenter: Valsamo Anagnostou, MD, PhD
Date & Time: Tuesday, April 28, 3:05 PM - 3:20 PM CT
Location: Room S105 - McCormick Place South (Level 1)
Session: MS.CL01.02 - Liquid Biopsy: Circulating Nucleic Acids
Title: Cell-free DNA fragmentomes for treatment response monitoring in patients with metastatic colorectal cancer: the DOLPHIN study
Presenting Author: Denise E. Van Steijn
Date & Time: Tuesday, April 28, 2:00 PM - 5:00 PM CT
Poster Number: Section 29, Poster 6
Session: PO.CL01.03 - Liquid Biopsy: Circulating Nucleic Acids 1
